GlassScriptPhysician profile
Gary C Visser
NPI 1710170568
$3,849.98
in general payments reported to CMS, 2019-2025
38 companies · $792 in 2025
The $792 reported for 2025 was more than what 87% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
See the full distribution for Sports Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $259 · 2021: $613 · 2022: $362 · 2023: $732 · 2024: $744 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,268.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $581.74 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $504.92 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $452.35 | 2021-2025 | Qulipta, Ubrelvy |
| Pfizer INC. | $330.01 | 2019-2025 | |
| Lilly USA, LLC | $252.58 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $234.43 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $229.82 | 2019-2024 | Shingrix, Arexvy |
| Amgen INC. | $192.47 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $181.16 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Scientific Affairs, LLC | $90.33 | 2021 | |
| Genentech USA, INC. | $80.13 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $76.17 | 2022 | |
| Tolmar, INC. | $64.66 | 2023-2025 | Jatenzo |
| Astellas Pharma US INC | $58.66 | 2024-2025 | Veozah |
| Kaleo, INC. | $44.01 | 2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $38.52 | 2019 | |
| Gilead Sciences, INC. | $38.16 | 2019 | |
| Shire North American Group INC | $35.64 | 2019 | |
| Idorsia Pharmaceuticals US INC | $27.15 | 2022-2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $24.36 | 2021 | |
| Amarin Pharma, INC. | $22.76 | 2020 | |
| Aimmune Therapeutics, INC. | $21.32 | 2025 | Zenpep |
| Pacira Therapeutics, INC. | $20.90 | 2021 | |
| Convatec INC. | $20.84 | 2025 | |
| Organogenesis INC. | $20.21 | 2023 | Puraply |
| Optinose US, INC. | $19.69 | 2022 | |
| Depuy Synthes Sales INC. | $19.35 | 2020 | |
| Phadia US INC. | $18.81 | 2025 | Immunocap |
| Novartis Pharmaceuticals Corporation | $18.38 | 2022 | |
| Corcept Therapeutics | $17.03 | 2025 | Korlym |
| Ironwood Pharmaceuticals, INC | $17.01 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.08 | 2020 | |
| Eisai INC. | $14.99 | 2021 | |
| Sanofi Pasteur INC. | $14.73 | 2023 | |
| Tris Pharma INC | $14.41 | 2022 | |
| Biomerieux INC | $13.37 | 2023 | |
| Merck Sharp & Dohme LLC | $12.66 | 2019 | |
| Allergan, INC. | $11.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Visser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.